

**Three Months Ended March 31,**

|                                | <u>2021</u>        | <u>2020</u>       |
|--------------------------------|--------------------|-------------------|
| License revenue                | \$ 486             | \$ -              |
| Research and development       | 59,934             | 659               |
| General and administrative     | <u>4,948</u>       | <u>1,398</u>      |
| Loss from operations           | <u>(64,396)</u>    | <u>(2,057)</u>    |
| Net loss                       | <u>\$ (65,567)</u> | <u>\$ (2,467)</u> |
| Net loss per common share      | <u>\$ (1.25)</u>   | <u>\$ (0.11)</u>  |
| Weighted average common shares | <u>52,655,756</u>  | <u>22,854,106</u> |

**March 31, 2021 December 31, 2020**

|                           |                  |                  |
|---------------------------|------------------|------------------|
| Cash and cash equivalents | \$ <u>92,892</u> | \$ <u>67,737</u> |
| Current assets            | \$ 98,758        | \$ 68,212        |
| Current liabilities       | <u>53,255</u>    | <u>20,415</u>    |
| Working Capital           | <u>\$ 45,503</u> | <u>\$ 47,797</u> |